INmune Bio Partners With Uniphar for Ebstrocel Access
The company secures a distribution deal to expand access to its investigational therapy in Europe and MENA markets.
Updated on Oct. 21, 2026 in Biotech
Live Poll
Do you trust that biotech firms are prioritizing patient access as they scale their global infrastructure?
INmune Bio has signed a Master Services Agreement with Uniphar Durbin Ireland Limited to facilitate international access to Ebstrocel. This collaboration enables named-patient access to the investigational allogeneic stromal cell therapy across selected European and MENA countries.
Why it matters
The partnership allows INmune Bio to establish a capital-efficient international commercial infrastructure. It provides a pathway to market without the need to build individual capabilities in every specific region.
Uniphar maintains a network spanning 160 countries and supports its operations with more than 3,600 staff members. The firm leverages 57 years of experience to manage regulatory assessments and distribution logistics for over 200 multinational clients.
The players
INmune Bio
This is a biotech company headquartered in Boca Raton, Florida, that focuses on developing treatments for diseases involving the immune system.
Uniphar Durbin Ireland Limited
This is an Irish healthcare services firm that provides global distribution, market access, and regulatory support for pharmaceutical and medical technology products.
Krystal Biotech
This is a gene therapy company that gained regulatory approval for its own therapy targeting epidermolysis bullosa.
Abeona Therapeutics
This is a clinical-stage biopharmaceutical company that received US regulatory approval for its therapy Zevaskyn in 2025.
The details
The agreement covers regulatory feasibility, storage, and distribution services for Ebstrocel, which is currently in development for recessive dystrophic epidermolysis bullosa. INmune Bio intends to leverage this framework before pursuing formal marketing authorizations in the UK and EU.
Timeline
October 21, 2026: The Master Services Agreement between INmune Bio and Uniphar is signed.
May 2023: Krystal Biotech received US approval for Vyjuvek.
April 2025: Abeona Therapeutics received US approval for Zevaskyn, while Vyjuvek gained EU approval.
2026: INmune Bio plans to submit a marketing authorisation application to the UK MHRA.
2027: INmune Bio plans to submit a marketing authorisation application to the EU EMA.
The Tech Race
This deal follows the 2025 approval of Vyjuvek and Zevaskyn for epidermolysis bullosa, signaling a shift in how firms prepare for international commercialization in rare disease markets. The move positions INmune Bio to compete in a field where established rivals have already secured regulatory milestones.
The agreement facilitates named-patient access to Ebstrocel for individuals in participating countries who are currently awaiting a regulatory-approved treatment. This provides a direct path for patients to access the therapy before full-scale commercial availability begins in the UK or EU.
The takeaway
This partnership highlights the strategic shift toward using established distribution networks to bypass the high cost of building internal international infrastructure. Companies focusing on rare diseases often utilize these frameworks to accelerate patient access while preparing for formal regulatory filings.
Further reading
Learn more about the latest developments in Biotech.
Live Poll
Do you trust that biotech firms are prioritizing patient access as they scale their global infrastructure?
